Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect

Hyperkalemia, a potential life threating condition, is a commonly encountered problem in chronic kidney disease (CKD) patients. Patiromer acetate, a nonabsorbable cation exchange polymer, is a gastrointestinal agent for chronic therapy in patients with persistent hyperkalemia. Patiromer is generally...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in nephrology 2019, Vol.2019 (2019), p.1-4
Main Authors: Sarac, Erdal, Man Singh Dangol, Gulshan, Pupillo, Stephen, Bhattarai, Shreeyukta
Format: Article
Language:English
Subjects:
Case Report
Case reports
Chronic illnesses
Diabetes
Drug stores
Enzymes
Family medical history
Homeostasis
Hypertension
Kidney diseases
Nephrology
Patients
Physiology
Polymers
Potassium
Urine
Vitamin D
Vitamin deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperkalemia, a potential life threating condition, is a commonly encountered problem in chronic kidney disease (CKD) patients. Patiromer acetate, a nonabsorbable cation exchange polymer, is a gastrointestinal agent for chronic therapy in patients with persistent hyperkalemia. Patiromer is generally well tolerated in patients; common side effects are gastrointestinal, such as diarrhea, constipation, flatulence, and vomiting. Hypercalcemia, although a theoretical possibility, has not been reported in any major clinical trials. We present a case of hypercalcemia associated with patiromer acetate used for treatment of hyperkalemia in a stage IV CKD patient. Clinicians should be aware of the possibility of hypercalcemia while taking patiromer.
ISSN:2090-6641
2090-665X
DOI:10.1155/2019/3507407